MedPath

Association of first trimester maternal serum analytes with adverse pregnancy outcomes 1 year obseravtional study at KAHERS Dr. Prabhakar Kore hospital and medical research cetre

Not Applicable
Conditions
Health Condition 1: O351- Maternal care for (suspected) chromosomal abnormality in fetus
Registration Number
CTRI/2022/06/043093
Lead Sponsor
Dr Cheyne Rosetta Estibeiro
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1)All pregnant women between 9 weeks and 13 weeks 6 days POG presenting for the first trimester visit to OPD

2)Participants who are consenting for enrollment in the study

Exclusion Criteria

1)women with major ultrasonic or chromosomal abnormalities

2)k/c/o insulin dependent diabetes mellitus

3)chronic hypertension

4)cardiac disorder

5)renal disorder

6)multiple gestation

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
to assess the association between Beta HCG PLGF and associated PAPP A From 12 weeks period of gestation until 13 weeks 6 days period of gestation with adverse pregnancy outcomes such as preeclampsia, FGR, Pre term delivery, Oligohydramnios, low birth weight, abruptio placenta, Intra uterine death, chromosomal anomalies.Timepoint: From 12 weeks period of gestation until 13 weeks 6 days period of gestation <br/ ><br>next post delivery in peurperium
Secondary Outcome Measures
NameTimeMethod
ILTimepoint: NI
© Copyright 2025. All Rights Reserved by MedPath